title: PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.
abstract: The PICALM-MLLT10 fusion gene, generated by the t(10;11)(p12-13;q14-21) translocation, is a rare but recurrent event in acute leukemias. In this study, we assessed the characteristics and outcome of 18 PICALM-MLLT10 AML patients. As compared with non PICALM-MLLT10 patients (n=72), PICALM-MLLT10 AML were characterized by more frequent extramedullary diseases, CD7 expression and higher platelet counts. Three out of four therapy-related PICALM-MLLT10 AMLs had been previously treated for diffuse large B-cell lymphoma. The complete response rate was 71% after intensive chemotherapy. PICALM-MLLT10 patients had a shorter median overall survival than patients with favorable cytogenetics (12 months vs. not reached, p=0.07) but not significantly different from those of intermediate (26 months, p=0.32) or unfavorable cytogenetic groups (8 months, p=0.13). Long term responses were achieved in a subset of patients after allogeneic stem-cell transplantation but also after high-dose cytarabine.
authors.affiliation: Service d'Hématologie, CHU de Toulouse, Hôpital Purpan, 31059 Toulouse, France. cecileborel@yahoo.fr
authors.forename: Cecile
authors.initials: C
authors.lastname: Borel
authors.forename: Nicole
authors.initials: N
authors.lastname: Dastugue
authors.forename: Valérie
authors.initials: V
authors.lastname: Cances-Lauwers
authors.forename: Marie-Joelle
authors.initials: MJ
authors.lastname: Mozziconacci
authors.forename: Thomas
authors.initials: T
authors.lastname: Prebet
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
authors.forename: Aranud
authors.initials: A
authors.lastname: Pigneux
authors.forename: Eric
authors.initials: E
authors.lastname: Lippert
authors.forename: Sorin
authors.initials: S
authors.lastname: Visanica
authors.forename: Faezeh
authors.initials: F
authors.lastname: Legrand
authors.forename: Jean Philippe
authors.initials: JP
authors.lastname: Rault
authors.forename: Sylvie
authors.initials: S
authors.lastname: Taviaux
authors.forename: Christian
authors.initials: C
authors.lastname: Bastard
authors.forename: Francine
authors.initials: F
authors.lastname: Mugneret
authors.forename: Marie Agnes
authors.initials: MA
authors.lastname: Collonges Rames
authors.forename: Nathalie
authors.initials: N
authors.lastname: Gachard
authors.forename: Pascaline
authors.initials: P
authors.lastname: Talmant
authors.forename: Eric
authors.initials: E
authors.lastname: Delabesse
authors.forename: Christian
authors.initials: C
authors.lastname: Récher
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D015514:Oncogene Proteins, Fusion; C511819:PICALM-MLLT10 fusion protein, human